Franklin Resources Inc. Grows Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Franklin Resources Inc. raised its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 299.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 75,779 shares of the company's stock after purchasing an additional 56,816 shares during the quarter. Franklin Resources Inc.'s holdings in Recursion Pharmaceuticals were worth $512,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of RXRX. Vanguard Group Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after purchasing an additional 9,737,196 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock valued at $35,803,000 after acquiring an additional 656,003 shares during the last quarter. Norges Bank bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth $23,429,000. Charles Schwab Investment Management Inc. boosted its position in Recursion Pharmaceuticals by 17.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock worth $15,372,000 after purchasing an additional 333,323 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Recursion Pharmaceuticals by 6.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock valued at $7,751,000 after purchasing an additional 67,464 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Analyst Upgrades and Downgrades

RXRX has been the topic of several research reports. Morgan Stanley lowered their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Finally, Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Stock Up 3.4 %

Shares of Recursion Pharmaceuticals stock traded up $0.18 during midday trading on Friday, hitting $5.50. The company had a trading volume of 12,710,040 shares, compared to its average volume of 12,041,123. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market capitalization of $2.21 billion, a P/E ratio of -3.59 and a beta of 1.00. The company has a 50 day moving average of $6.62 and a 200 day moving average of $6.79.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm's revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.42) EPS. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.